Silver Book Fact

TAVR improves quality of life in SAS patients

Fact image

Kovac J, Schuler G, Gerckens U, Muller R, et al. Four-Year Experience with CoreValve Transcatheter Heart Valve. EuroInterven. 2016; 12(8). https://pubmed.ncbi.nlm.nih.gov/27159659/

Reference

Title
Four-Year Experience with CoreValve Transcatheter Heart Valve
Publication
EuroInterven
Publication Date
2016
Authors
Kovac J, Schuler G, Gerckens U, Muller R, et al.
Volume & Issue
Volume 12, Issue 8
Pages
1039-46
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • Satisfaction with HVD Treatment
    Among treated heart valve disease (HVD), 96% express “full satisfaction” and 78% are “very satisfied” with their treatment.  
  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
  • TAVR improves quality of life in SAS patients
     
  • Life expectancy and quality of life gains from AVR
    A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…